Skip to main content
Top
Published in: Endocrine Pathology 2/2008

01-06-2008

Clinicopathological Features of Growth Hormone-producing Pituitary Adenomas: Difference among Various Types Defined by Cytokeratin Distribution Pattern Including a Transitional Form

Authors: Abdulkader Obari, Toshiaki Sano, Kenichi Ohyama, Eiji Kudo, Zhi Rong Qian, Akiko Yoneda, Nasim Rayhan, Muhammad Mustafizur Rahman, Shozo Yamada

Published in: Endocrine Pathology | Issue 2/2008

Login to get access

Abstract

Pituitary adenomas producing almost exclusively growth hormones (GH) have been ultrastructurally classified into two distinct types: densely granulated somatotroph (DG) adenomas and sparsely granulated (SG) adenomas. Fibrous body (FB), an intracytoplasmic globular aggregation of cytokeratin (CK) filaments, is a hallmark of SG adenomas. Under light microscope, FB could be identified by CK immunohistochemistry as a dot-pattern immunoreaction versus a perinuclear pattern for cells without FB. However, it has been noted that numerous adenomas contain mixed populations of the two patterns. To clarify clinicopathological characteristics of the adenomas with mixed populations (“intermediate type” adenomas) and to confirm clinicopathological differences between strictly defined DG-type and SG-type adenomas, we performed this study on 104 GH cell adenomas. Having segregated “intermediate-type” adenomas (26 cases), we found significant differences between typical DG-type (47 cases) and SG-type adenomas (31 cases); SG-type adenomas had younger ages (44 vs. 50), higher frequency of macroadenomas (86% vs. 58%), invasiveness (65% vs. 38%), advanced grades (3 or 4) in Knosp’s classification (50% vs. 24%), and weaker immunoreaction for GH, β-TSH, α-subunit, E-cadherin, and β-catenin. Clinicopathological characteristics of “intermediate-type” adenomas were identical to those of DG-type adenomas. These findings confirm that SG-type adenoma is a distinct section of GH cell adenomas with special properties and biological behavior, and suggest that intermediate-phenotype adenomas are enrolled in DG-type adenomas. Special properties and biological behavior of SG-type adenomas may appear after the majority of tumor cells possess a fully developed fibrous body.
Literature
1.
go back to reference Asa SL. Tumors of the pituitary gland. In: Rosai J, ed. Atlas of tumor pathology (Third Series Fascicle 22). Washington DC, PA: Armed Forces Institute of Pathology, pp. 47–149, 1998. Asa SL. Tumors of the pituitary gland. In: Rosai J, ed. Atlas of tumor pathology (Third Series Fascicle 22). Washington DC, PA: Armed Forces Institute of Pathology, pp. 47–149, 1998.
2.
go back to reference Horvath E, Kovacs K. The adenohypophysis. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. vol 1. Boston, PA: Blackwell, pp. 245–81, 1991. Horvath E, Kovacs K. The adenohypophysis. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. vol 1. Boston, PA: Blackwell, pp. 245–81, 1991.
3.
go back to reference Kontogeorgos G, Watson Jr RE, Lindell EP. Growth hormone producing adenoma. In: DeLellis RA, Lioyd RV, Heitz PU, Eng C, eds. Pathology and genetics of tumors of endocrine organs (Series of: World Health Organization Classification of Tumors). Lyon, PA: IARC Press, pp. 14–9, 2004. Kontogeorgos G, Watson Jr RE, Lindell EP. Growth hormone producing adenoma. In: DeLellis RA, Lioyd RV, Heitz PU, Eng C, eds. Pathology and genetics of tumors of endocrine organs (Series of: World Health Organization Classification of Tumors). Lyon, PA: IARC Press, pp. 14–9, 2004.
4.
go back to reference Horvath E, Kovacs K. Morphogenesis and significance of fibrous bodies in human pituitary adenomas. Virchows Arch B Cell Pathol 27:69–78, 1978.PubMed Horvath E, Kovacs K. Morphogenesis and significance of fibrous bodies in human pituitary adenomas. Virchows Arch B Cell Pathol 27:69–78, 1978.PubMed
5.
go back to reference Neumann PE, Goldman JE, Horoupian DS, et al. Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Arch Pathol Lab Med 109:505–8, 1985.PubMed Neumann PE, Goldman JE, Horoupian DS, et al. Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Arch Pathol Lab Med 109:505–8, 1985.PubMed
6.
go back to reference Kasper M, Stosiek P, Van Muijen GNP, et al. Cell type heterogeneity of intermediate filament expression in epithelia of the human pituitary gland. Histochemistry 93:93–103, 1989.PubMedCrossRef Kasper M, Stosiek P, Van Muijen GNP, et al. Cell type heterogeneity of intermediate filament expression in epithelia of the human pituitary gland. Histochemistry 93:93–103, 1989.PubMedCrossRef
7.
go back to reference Yamada S, Aiba T, Sano T, et al. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20–7, 1993.PubMedCrossRef Yamada S, Aiba T, Sano T, et al. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20–7, 1993.PubMedCrossRef
8.
go back to reference Sano T, Ohshima T, Yamada S. Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 187:530–3, 1991.PubMed Sano T, Ohshima T, Yamada S. Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 187:530–3, 1991.PubMed
9.
go back to reference Bando H, Sano T, Ohshima T, et al. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39:355–63, 1992.PubMed Bando H, Sano T, Ohshima T, et al. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39:355–63, 1992.PubMed
10.
go back to reference Sano T, Yamada S, Hirose T, et al. Cytokeratin distribution and functional properties of growth hormone-producing pituitary adenomas. Endocr Pathol 5:107–13, 1994.CrossRef Sano T, Yamada S, Hirose T, et al. Cytokeratin distribution and functional properties of growth hormone-producing pituitary adenomas. Endocr Pathol 5:107–13, 1994.CrossRef
11.
go back to reference Mazal PR, Czech T, Sedivy R, et al. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of acromegalic patients. Clin Neuropathol 20:163–71, 2001.PubMed Mazal PR, Czech T, Sedivy R, et al. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of acromegalic patients. Clin Neuropathol 20:163–71, 2001.PubMed
12.
go back to reference Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–5, 2005.PubMedCrossRef Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–5, 2005.PubMedCrossRef
13.
go back to reference Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT, eds. Diagnosis and treatment of pituitary tumors. Int Congress Series No. 303. Amsterdam: Exerpta Medica, pp. 179–98, 1973. Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT, eds. Diagnosis and treatment of pituitary tumors. Int Congress Series No. 303. Amsterdam: Exerpta Medica, pp. 179–98, 1973.
14.
go back to reference Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–7, 1993.PubMedCrossRef Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–7, 1993.PubMedCrossRef
15.
go back to reference Xu B, Sano T, Yoshimoto K, Yamada S. Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 13:341–51, 2002.PubMedCrossRef Xu B, Sano T, Yoshimoto K, Yamada S. Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 13:341–51, 2002.PubMedCrossRef
16.
go back to reference Sano T, Rong QZ, Kagawa N, et al. Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–32, 2004.PubMedCrossRef Sano T, Rong QZ, Kagawa N, et al. Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–32, 2004.PubMedCrossRef
17.
go back to reference Yamada S, Sano T, Stefaneanu L, et al. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 76:352–6, 1993.PubMedCrossRef Yamada S, Sano T, Stefaneanu L, et al. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 76:352–6, 1993.PubMedCrossRef
18.
go back to reference Wick MR. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 17:194–203, 2000.PubMed Wick MR. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 17:194–203, 2000.PubMed
19.
go back to reference Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. Am J Dermatopathol 21:16–20, 1999.PubMedCrossRef Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. Am J Dermatopathol 21:16–20, 1999.PubMedCrossRef
20.
go back to reference Haas JE, Palmer NF, Weinberg AG, et al. Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol 12:646–57, 1981.PubMedCrossRef Haas JE, Palmer NF, Weinberg AG, et al. Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol 12:646–57, 1981.PubMedCrossRef
21.
go back to reference Saito T, Oda Y, Itakura E, et al. Expression of intercellular adhesion molecules in epithelioid sarcoma and malignant rhabdoid tumor. Pathol Int 51:532–42, 2001.PubMedCrossRef Saito T, Oda Y, Itakura E, et al. Expression of intercellular adhesion molecules in epithelioid sarcoma and malignant rhabdoid tumor. Pathol Int 51:532–42, 2001.PubMedCrossRef
22.
go back to reference Asa SL, Digiovanni R, Jiang J, et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67:7505–11, 2007.PubMedCrossRef Asa SL, Digiovanni R, Jiang J, et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67:7505–11, 2007.PubMedCrossRef
Metadata
Title
Clinicopathological Features of Growth Hormone-producing Pituitary Adenomas: Difference among Various Types Defined by Cytokeratin Distribution Pattern Including a Transitional Form
Authors
Abdulkader Obari
Toshiaki Sano
Kenichi Ohyama
Eiji Kudo
Zhi Rong Qian
Akiko Yoneda
Nasim Rayhan
Muhammad Mustafizur Rahman
Shozo Yamada
Publication date
01-06-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 2/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9029-z

Other articles of this Issue 2/2008

Endocrine Pathology 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.